The role of N-glycosylation in transport function and surface targeting of the human solute carrier PAT1  by Dorn, Madlen et al.
FEBS Letters 583 (2009) 1631–1636journal homepage: www.FEBSLetters .orgThe role of N-glycosylation in transport function and surface targeting
of the human solute carrier PAT1
Madlen Dorn a,b, Michael Jaehme a,1, Matthias Weiwad c, Fritz Markwardt d, Rainer Rudolph a,
Matthias Brandsch b, Eva Bosse-Doenecke a,*
a Institute of Biochemistry/Biotechnology, Faculty of Science I, Martin-Luther-University Halle-Wittenberg, D-06120 Halle, Germany
bBiozentrum of the Martin-Luther University Halle-Wittenberg, D-06120 Halle, Germany
cMax-Planck Research Unit ‘‘Enzymology of Protein Folding”, D-06120 Halle, Germany
d Institute of Physiology, Faculty of Medicine, Martin-Luther-University Halle-Wittenberg, D-06097 Halle, Germanya r t i c l e i n f o
Article history:
Received 17 March 2009
Revised 21 April 2009
Accepted 21 April 2009
Available online 3 May 2009
Edited by Peter Brzezinski
Keywords:
hPAT1
Solute carrier
Glycosylation
Peptide: N-glycosidase F
Xenopus laevis oocyte0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.04.037
Abbreviations: HA, hemagglutinin; LYAAT1, lysoso
PAT1, proton-coupled amino acid transporter 1; PAGE
phoresis; PNGase F, Peptide: N-glycosidase F; SLC, sol
laevis
* Corresponding author. Fax: +49 345 5527013.
E-mail address: eva.bosse-doenecke@biochemtech
necke).
1 Present address: Max-Planck-Institute of Biophys
Membrane Biology, 60438 Frankfurt am Main, Germana b s t r a c t
In the present study we show in the Xenopus laevis expression system that the proton-coupled
amino acid transporter 1 (PAT1, SLC36A1) is glycosylated at asparagine residues N174, N183 and
N470. To determine the functional role of N-glycosylation, glycosylation-deﬁcient mutants were
analyzed by two-electrode voltage-clamp measurements after expression in X. laevis oocytes. Single
replacements of asparagine residues had no effect on transport activity. However, multiple substi-
tutions resulted in a decreased transport rate, leaving Kt unchanged. Immunoﬂuorescence localisa-
tion revealed a diminished plasma membrane expression of glycosylation-defective mutants. This
indicates that N-glycans are not required for transport function, but are important for membrane
targeting.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The proton-coupled amino acid transporter 1 (PAT1, LYAAT1,
SLC36A1) is a member of the family 36 of the second largest group
of membrane proteins, the solute carriers (SLC). It is mainly ex-
pressed in the apical membrane of intestinal epithelial cells, where
it mediates the absorption of many amino acids originating from
luminal protein digestion as well as free amino acids such as tau-
rine. PAT1 cDNA was ﬁrst cloned from rat brain and described as
the lysosomal amino acid transporter (LYAAT1) [1]. Shortly there-
after, cloning from mouse small intestine [2] and from the human
cell line Caco-2 [3] was reported. In addition to these tissues, PAT1
mRNA was also detected in liver, colon, lung, spleen and placenta
[1–3]. Substrates for the transporter are small neutral amino acidschemical Societies. Published by E
mal amino acid transporter;
, polyacrylamide gel electro-
ute carrier; X. laevis, Xenopus
.uni-halle.de (E. Bosse-Doe-
ics, Department of Molecular
y.(e.g. L-proline and glycine), amino acid derivatives (e.g. c-aminobu-
tyric acid) and pharmaceutically relevant amino acid derivatives
(e.g. D-cycloserine and L-azetidine-2-carboxylic acid) [2–5]. Hence,
in addition to its physiological functions there is growing evidence
for PAT1 being an important drug transporter in the intestine
allowing oral administration of certain drugs and prodrugs. Trans-
port of substrates by PAT1 is driven by an inside directed proton
gradient. Very recently our group gathered evidence that the
highly conserved histidine residue 55 is responsible for binding
and translocation of the proton [6].
To increase our knowledge about structure–function relation-
ships we now focused on N-glycosylation as a major post-transla-
tional modiﬁcation of eukaryotic membrane proteins. Recent
results for other transport proteins suggest that fundamental prop-
erties of membrane proteins such as folding, stability, localisation
and ligand binding can be affected by N-glycosylation [7–9]. There-
fore, we were interested in its role for the function of human PAT1.
Based on the primary structure of hPAT1, seven consensus sites for
N-linked glycosylation can be identiﬁed. In case of an intracellular
or membrane localisation the predicted sites will not be utilized.
According to the 11-transmembrane domain topology model
[10], three of them (N174, N183 and N470) are located at extracel-
lular loops and could be glycosylated (Fig. 1).lsevier B.V. All rights reserved.
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Fig. 1. 11-Transmembrane domain topology model of hPAT1 [10]. Potential N-glycosylation sites at asparagine residues 174, 183 and 470 are indicated.
1632 M. Dorn et al. / FEBS Letters 583 (2009) 1631–1636In the present study we performed site-directed mutagenesis of
residues N174, N183 and N470 individually or in combination. We
investigated by expression in X. laevis oocytes which of the poten-
tial sites are actually glycosylated and analyzed the consequence of
the elimination of these sites on the transport function and target-
ing of the protein.
2. Materials and methods
2.1. Materials
Chemical reagents were from Sigma (Taufkirchen, Germany).
The following antibodies were used: polyclonal rabbit anti-HA-
tag antibody (Sigma), monoclonal mouse anti-HA-tag antibody,
goat anti-mouse horseradish peroxidase conjugated antibody (San-
ta Cruz Biotechnology Inc., Heidelberg, Germany) and AlexaFlu-
or488 goat anti-rabbit antibody (Invitrogen). Peptide: N-
Glycosidase F (PNGase F) was purchased from New England Biolabs
(Frankfurt a. M., Germany).
2.2. Construction of N-glycosylation mutants of hPAT1
The Xenopus laevis oocyte expression vector pNKS was kindly
provided by G. Schmalzing (RWTH, Aachen, Germany) as pNKS-
transducin. The murine transducin was replaced by the PCR-ampli-
ﬁed cDNA of hPAT1 containing an N-terminal HA-tag (pNKS-HA-
hPAT1). A previous study from our group [6] showed that HA-
tagged hPAT1 retained the functional properties of the unmodiﬁed
protein. The wildtype HA-tagged cDNA of hPAT1 in the pSPORT1
vector (pSPORT1-HA-hPAT1) was used as template [6]. The inser-
tion of the correct cDNA was veriﬁed by sequencing (MWG Biotech
AG, Ebersberg, Germany).
To exchange the three potential N-glycosylation sites at aspara-
gine residues 174, 183 and 470 for glutamine residues, mutagene-
sis was performed using the QuikChange II Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) and appropriate muta-genic forward and reverse oligonucleotides (primer sequences will
be provided on request). The pNKS-HA-hPAT1 vector was used as
template. The insertion of the mutations and the correct cDNA se-
quence were conﬁrmed by DNA sequencing.
2.3. In vitro cRNA synthesis
The wildtype and mutant pNKS-HA-hPAT1 constructs served as
templates for cRNA synthesis. After linearising the plasmids with
NotI, cRNAs were synthesized using the mMESSAGE mMACHINE
SP6 kit (Ambion, Huntingdon, UK). The cRNAs were puriﬁed with
the MEGAclearTM kit (Ambion) and the concentration was deter-
mined by UV absorbance at 260 nm. The cRNAs were stored at
80 C.
2.4. Oocyte preparation and cRNA injection
Oocytes were surgically removed from anaesthetised X. laevis
frogs, dissected and defolliculated as described by Riedel and
coworkers [11]. In brief, for anesthesia tricaine methane sulfonate
(Sigma) was used. The removed oocytes were separated by collage-
nase treatment (2 mg/ml) for 2 h. Healthy stage V–VI oocytes were
manually selected and 23 nl (1.1 lg/ll) of wildtype or mutant
cRNA were injected per oocyte. Water-injected oocytes were used
as control. Injected oocytes were maintained at 19 C in modiﬁed
Barth’s medium (5 mM HEPES/NaOH, pH 7.4, 100 mM NaCl,
1 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 000 U/ml penicillin and
10 mg/ml streptomycin). Five to six days after injection electro-
physiological measurements and biochemical studies were
performed.
2.5. Two-electrode voltage-clamp experiments
Two-electrode voltage-clamp signals were recorded to assess
the electrogenic function of the surface expressed transport pro-
tein. Oocytes were placed in a ﬂow-through chamber and continu-
M. Dorn et al. / FEBS Letters 583 (2009) 1631–1636 1633ously superfused (75 ll/s) with oocyte Ringer (ORi) buffer (10 mM
Mes/Tris, pH 6.5, 100 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 2 mM
KCl) in the absence or presence of glycine at a concentration of
20 mM. Quick and reproducible solution exchanges were achieved
using a small tube-like chamber (0.1 ml) combined with fast
superfusion [12,13]. Microelectrodes with resistances between
0.8 and 1.4 MX were pulled of borosilicate glass and ﬁlled with
3 M KCl. Whole-cell currents were recorded and ﬁltered at
100 Hz using a two-electrode voltage-clamp ampliﬁer (OC-725C,
Hamden, USA) and sampled at 85 Hz. Oocytes were voltage
clamped at a membrane potential of 60 mV. Data were analyzed
using the Superpatch 2000 program (Julius-Bernstein-Institute of
Physiology, SP-Analyzer by T. Böhm, Halle, Germany). Currents in-
duced by application of 20 mM glycine (I20 Gly) were calculated as
the difference of the currents measured in the presence and ab-
sence of substrate. Statistical values are expressed as mean-
s ± S.E.M. from measurements of 6–8 oocytes each from two
batches of oocyte preparation. The statistical signiﬁcance
(P < 0.01, P < 0.001) of the differences was determined by t-test
analysis.
The Michaelis constants for the dependence of the transport
rate on substrate concentration (Kt) were derived from experi-
ments with increasing glycine concentrations (0–100 mM) at pH
6.5 in ORi buffer. Mean values ± S.E.M. were calculated from mea-
surements of eight oocytes and the kinetic constants were ob-
tained by nonlinear regression of the Michaelis–Menten plot
(SigmaPlot, Systat Software GmbH, Erkrath, Germany).
2.6. Immunoﬂuorescence of cRNA injected X. laevis oocytes
Oocytes expressing either wildtype or mutant transporter were
ﬁxed with ethanol/acetic acid (95:5) for 1.5 h at 4 C. After washing
with 5% BSA/PBS several times they were incubated overnight at
4 C with the primary antibody (rabbit anti-HA tag) diluted
1:1600 in 5% BSA/PBS followed by incubation for 1 h at room tem-
perature with the secondary antibody (goat anti-rabbit AlexaFlu-
or488) 1:500 in 5% BSA/PBS. Oocytes were washed with 5% BSA/
PBS and then mounted on microscope slides using CitiFluor (Pla-
no, Wetzlar, Germany). Images were obtained using a confocal la-
ser scanning microscope (Nikon ECLIPSE TE2000). Fluorescence
intensities of 11 equal segments of each oocyte membrane were
quantiﬁed using Aida 2.1 image measurement software (Raystad,
Straubenhardt, Germany). Mean values were calculated from mea-
surements of 5–6 oocytes.
2.7. Preparation of oocyte homogenates and PNGase F treatment
Oocytes expressing either wildtype or mutant HA-hPAT1 were
homogenized in 20 ll of lysis buffer (20 mM Tris/HCl, pH 7.4,
100 mM NaCl, 1% Triton X-100, 1 protease inhibitor (complete
mini, Roche, Germany) per oocyte. After centrifugation of solubi-
lized oocytes (16 000 g, 15 min, 4 C) 8 ll of the supernatant was
supplemented with 1 ll of G7 reaction buffer and 1 ll of PNGase
F (500 U/ll) or water (± PNGase F). Samples were analyzed by
SDS–PAGE (7.5%) and immunoblotting.
2.8. Immunoblotting of oocyte homogenates
Proteins were separated by SDS–PAGE and electrotransferred
onto nitrocellulose membranes. After blocking of membranes in
5% non-fat dry milk in TBT buffer (50 mM Tris, pH 7.4, 150 mM
NaCl, 0.2% Tween) for 1 h at room temperature, Western blots were
probed with the primary antibody (mouse anti-HA tag) diluted
1:1000 in 5% non-fat dry milk in TBT buffer overnight at 4 C.
The secondary antibody (goat anti-mouse horseradish peroxidase
conjugated antibody) was used at a dilution of 1:2000 in 5% non-fat dry milk in TBT buffer for 1 h at room temperature. Antibody
binding was detected by enhanced chemiluminescence.3. Results and discussion
3.1. N-Glycosylation of hPAT1
The 11-transmembrane domain topology model for hPAT1 sug-
gests three extracellular consensus sites for potential N-glycosyla-
tion, i.e. asparagine residues 174, 183 and 470 (Fig. 1). These
residues are conserved in human, rat and mouse PAT1. Whether
these sites are indeed glycosylated in vivo is not known so far. To
address this issue, lysates of X. laevis oocytes injected with the
cRNA of hPAT1 were incubated with PNGase F to remove possible
N-linked carbohydrate chains at canonical consensus sequences.
Western blots of untreated lysates (PNGase F) show a single band
with an apparent molecular mass of 50 kDa (Fig. 2A). After incu-
bation with PNGase F the molecular mass shifted to a smaller size
of 45 kDa. These results clearly show that hPAT1 is glycosylated
in the oocytes.
To analyze which of the three putative consensus sequences is
utilized for glycosylation, glycosylation sites were deleted individ-
ually by site-directed mutagenesis replacing the respective aspar-
agine by glutamine residues. Glutamine was used as a
conservative loss of function substitution with minimal structural
impact. The cRNA of the resultant mutants N174Q, N183Q and
N470Q was injected into X. laevis oocytes and lysates were ana-
lyzed by SDS–PAGE and immunoblotting. As shown in Fig. 2B
mutation of each of the potential N-glycosylation sites resulted
in faster migration of the expressed protein, consistent with a loss
of N-linked carbohydrate chains from the protein. Next, three dou-
ble mutants were created (N174/183Q, N183/470Q and N470/
174Q). Western blots of lysates of cRNA injected Xenopus oocytes
showed an additional change in migration behavior of the double
mutants compared to the single mutants of hPAT1 (Fig. 2B). Inter-
estingly, the lysates of all three double mutants showed an addi-
tional upper band which disappears after PNGase F treatment.
This results in one single band at the same migration height as of
PNGase F treated wildtype protein (Fig. 2C). We assume that these
bands represent immature glycosylation species. As N-linked gly-
cans play an important role in quality control in the endoplasmatic
reticulum, the absence of two N-linked glycans might lead to an
impaired processing of the high-mannose core complex added in
the beginning of the glycosylation process. This would lead to
the observed species with slow migration behavior. Finally, a triple
mutant was generated obliterating all three N-glycosylation sites
(N174/183/470Q). Lysates of oocytes expressing the triple mutant
showed a further reduction of the molecular mass compared to the
double mutants (Fig. 2B), indicating another loss of N-linked gly-
cans. Furthermore, incubation of oocyte lysate containing the triple
mutant with PNGase F revealed no further shift compared to non-
treated mutant transport protein and the mobility was similar to
the PNGase F treated wildtype hPAT1 (Fig. 2D). These data show
very clearly that (i) each residue, N174, N183 and N470 is glycos-
ylated and that (ii) hPAT1 contains no further sites for N-glycosyl-
ation. These ﬁndings support the transmembrane model in Fig. 1.
Using a similar approach a 12-transmembrane domain structure
of the organic anion transport protein oatp1a1 could be veriﬁed
[14].
3.2. Effect of N-glycosylation site mutation on hPAT1 transport
function
To address the role of N-glycosylation on hPAT1 function, two-
electrode voltage-clamp measurements of oocytes expressing
PNGase F +
42 kDa
52 kDa
42 kDa
52 kDa
42 kDa
52 kDa
42 kDa
52 kDa
++ + + + + + +PNGase F
Fig. 2. Western blot analysis of Xenopus laevis oocyte lysates containing wildtype and glycosylation-deﬁcient mutants of hPAT1. (A) Lysate of oocytes expressing wildtype
hPAT1. (B and C) Lysates of oocytes expressing wildtype or mutant hPAT1. (D) Lysate of oocytes expressing the N174/183/470Q mutant. Wildtype and mutant proteins were
treated with (+) or without () PNGase F.
1634 M. Dorn et al. / FEBS Letters 583 (2009) 1631–1636wildtype and mutant transporters were performed. As shown in
Fig. 3, single disruption of the N-glycosylation sites N174 and
N470, respectively, had only a minor effect on electrogenic glycine
transport. The inward current induced by 20 mM glycine (I20 Gly) is
comparable to the wildtype transporter. Only the single mutant
N183Q showed a slight increase to 130% (P < 0.001) of the wild-
type current. Next, the impact of multiple replacements of glyco-
sylation sites on hPAT1 function was examined. For the double
mutants N174/183Q and N470/174Q the transport of glycine was
again similar to that in wildtype hPAT1, with 120% and 100% of
wildtype, respectively. In contrast, the mutant N183/470Q elicitedFig. 3. Functional characterisation of wildtype hPAT1 and glycosylation-deﬁcient
mutants using the two-electrode voltage-clamp technique. Water-injected oocytes
served as control. Inward currents induced by 20 mM glycine (I20 Gly) were
determined at pH 6.5 and are presented as percentage of wildtype hPAT1.
Means ± S.E.M. are presented, *P < 0.01, **P < 0.001.only 67% (P < 0.001) of wildtype hPAT1 current. Simultaneous re-
moval of all three glycosylation sites in the triple mutant N174/
183/470Q resulted in a dramatic reduction of transport activity.
The transport of glycine was reduced to 29% (P < 0.001) compared
to that of wildtype hPAT1.
To analyze whether any of these substitutions affects the afﬁn-
ity of the transporter for glycine, the Michaelis constant was deter-
mined for each mutant. As shown in Supplementary data (Fig. S1)
we determined a Kt for glycine transport of the wildtype trans-
porter of 13.2 ± 1 mM. This value corresponds very well to previ-
ously published data on mouse and human PAT1 transport
function [2,15–17]. Interestingly, the Kt values of the different mu-
tants were in the same range (Table 1).
These results clearly show that glycosylation at individual sites
is not absolutely required for the transport function of hPAT1.
However, multiple disruptions of N-glycosylation sites cause
reduction in I20 Gly in some cases but do not affect the apparent
afﬁnity of the carrier for its substrate. Therefore, the most likely
explanation for the lower I20 Gly in the two glycosylation-deﬁcient
mutants N183/470Q and N174/183/470Q is a decreased number of
functional transporter proteins in the plasma membrane. This
could be due to a reduced PAT1 protein synthesis, an impairedTable 1
Michaelis constants Kt for glycine transport of hPAT1 wildtype and glycosylation-
deﬁcient mutants.
Construct Kt value (mM)
Wildtype 13.2 ± 1.0
N174Q 12.6 ± 0.7
N183Q 13.4 ± 0.7
N470Q 13.3 ± 0.9
N174/183Q 12.9 ± 0.6
N183/470Q 13.9 ± 0.9
N470/183Q 14.3 ± 1.1
N174/183/470Q 13.0 ± 1.9
Fig. 4. Localisation of immunostained wildtype and glycosylation-deﬁcient mutant hPAT1 expressed in Xenopus laevis oocytes analyzed by confocal laser scanning
microscopy. Oocytes were injected either with water (control) or cRNAs of wildtype and mutant hPAT1 as indicated.
M. Dorn et al. / FEBS Letters 583 (2009) 1631–1636 1635hPAT1 targeting to the plasma membrane, a reduced transport
turnover rate of the carriers or protein instability. As shown by
the Western blot in Fig. 2B and C, the lysates of oocytes injected
with the different cRNAs all show comparable amounts of trans-
port protein. A reduced level of biosynthesis can therefore be ex-
cluded. Moreover, we did not detect any small molecular weight
bands which would suggest degradation of non-glycosylated
protein.
3.3. Cellular localisation of N-glycosylation mutants of hPAT1
In the next series of experiments, we examined whether the re-
duced transport rate in the glycosylation-deﬁcient mutant N174/
183/470Q was caused by reduced cell surface expression. For local-
isation of wildtype and mutant hPAT1 expressed in X. laevis oo-
cytes, immunoﬂuorescence was analyzed by confocal laser
scanning microscopy (Fig. 4). Single and double mutants N174/
183Q and N470/174Q were detected in the plasma membrane at
similar levels as the wildtype protein. A notably weaker staining
was observed for the mutant N183/470Q and the glycosylation-
deﬁcient mutant N174/183/470Q. Quantiﬁcation of ﬂuorescence
intensities revealed a 60 ± 7% (P < 0.001) and 75 ± 5% (P < 0.001)
reduction in surface expression of mutant N183/470Q and N174/
183/470Q, respectively. We conclude that the reduced transport
rates of this double and the triple mutant result from a lower abun-
dance of the deglycosylated proteins in the plasma membrane.
These ﬁndings agree with studies of several other transport pro-
teins where decreased transport rates of glycosylation-deﬁcient
mutants were caused by a reduced targeting to the membrane
[8,18,19].4. Conclusion
This study describes the impact of N-linked glycans on the bio-
chemical properties, function and targeting of the amino acid
transporter hPAT1. The shift of the molecular mass of hPAT1 ex-
pressed in X. laevis oocytes upon treatment with PNGase F implies
that one or more of the three potential glycosylation sites are in-
deed utilized. Site-directed mutagenesis and immunoblotting of
oocyte lysates expressing mutant transporters revealed that puta-
tive extracellular residues N174, N183 and N470 are each glycosyl-
ated and that hPAT1 contains no other glycosylation sites. These
results indirectly support the 11-transmembrane domain topology
model (Fig. 1).
A major aim of this study was to determine the functional role
of glycosylation. Analysis of the transporter properties after single
disruption of glycosylation sites showed that neither of them is
absolutely required for hPAT1 transport function. Multiple replace-
ments caused a reduced transport of glycine, coincident with a
diminished membrane expression. As a result, the triple mutant
was virtually unable to target to the membrane.Acknowledgements
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